Arthur Lubitz, MD
Allergy & Immunology · New York, NYNPI 1437348471
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $112,413 of the $164,798 with a category attached, or 68.2%. 37 manufacturers reported payments, led by AstraZeneca at 45.2% of the total. Among allergy & immunology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,052 payments — averaging $156.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$74K
- Incyte Corporation$32K
- Optinose US, Inc.$18K
- Novartis$9K
- Mylan Specialty L.p.$8K
- GSK$6K
- plus $17K from 31 others
Across 6 payments — averaging $5246.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$31K
What the payments were for
- Consulting fees$10,8737%
- Speaking & faculty fees$112,41368%
- Travel & lodging$7,5445%
- Food & beverage$33,79521%
- Education$1730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 257 | $74,421 |
| Incyte Corporation | 91 | $31,912 |
| Optinose US, Inc. | 46 | $17,880 |
| Novartis | 68 | $8,584 |
| Mylan Specialty L.p. | 28 | $8,365 |
| GSK | 209 | $6,446 |
| Sanofi | 89 | $4,453 |
| Teva Pharmaceuticals USA, Inc. | 6 | $2,515 |
| Genentech USA, Inc. | 6 | $1,618 |
| Regeneron Healthcare Solutions, Inc. | 26 | $1,190 |
| AbbVie | 45 | $1,066 |
| Regeneron | 9 | $803 |
| Alk-abello, Inc | 10 | $707 |
| LEO Pharma Inc. | 14 | $596 |
| CSL Behring | 24 | $595 |
| Pfizer | 26 | $579 |
| Kaleo, Inc. | 23 | $532 |
| Amgen | 13 | $362 |
| Biocryst US Sales Co., LLC | 2 | $228 |
| Galderma Laboratories, L.p. | 3 | $228 |
| Mallinckrodt Hospital Products Inc. | 8 | $228 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $213 |
| Organon | 5 | $213 |
| Grifols USA, LLC | 6 | $208 |
| Greer Laboratories, Inc. | 4 | $207 |
| Sunovion Pharmaceuticals Inc. | 10 | $145 |
| Blueprint Medicines Corporation | 1 | $90 |
| Hikma Pharmaceuticals USA | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Tersera Therapeutics LLC | 2 | $58 |
| Lilly USA, LLC | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Encore Dermatology Inc. | 2 | $35 |
| Pharming Healthcare, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Phadia US Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$164,798 in reported general payments places this provider in the 95th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 49 | $190,265 |
| XolairOmalizumab | 50 | $124,942 |
| TezspireTezepelumab-Ekko | 27 | $123,031 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $69,465 |
| Dupixent SyringeDupilumab | 12 | $43,888 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $29,320 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $17,657 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,666 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $3,601 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $3,353 |
| Azelastine Hcl | 189 | $2,521 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $2,312 |
| Epinephrine | 13 | $2,219 |
| Colchicine | 11 | $954 |
| Ipratropium Bromide | 54 | $903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $74,421 | $144,28972 claims |
| CSL BehringPrivigen | $595 | $69,46513 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $6,446 | $33,98758 claims |
| Hikma Pharmaceuticals USAEpinephrine | $84 | $2,21913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in New York
- Ujwala KazaNew York$1.1M
- Robert SporterNew York$946K
- Richard InselNew York$269K
- Purvi ParikhNew York$183K
- Ama AlexisNew York$120K
- Boyan HadjievNew York$97K
- Charlotte Cunningham-RundlesNew York$95K
- Paula BusseNew York$95K
- Hale YarmohammadiNew York$71K
- Joyce YuNew York$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.